Super‐enhancers exert a major role in the progression of various tumor types including PCa (Baumgart et al., 2019; He et al., 2019; Zuber et al., 2017) and also contribute to resistance mechanisms involving SE‐binding factors such as BRD4 or FOXP1 (Bao et al., 2019; Chen et al., 2019; Natsume et al., 2019). Here, FOXP1 is linked to neoplasm.